Rabeprazole ER

DRUG2 trials

Sponsors

Eisai Inc.

Conditions

Gastroesophageal Reflux Disease (GERD)

Phase 3

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

CompletedNCT00838526

Eisai Inc.Gastroesophageal Reflux Disease (GERD)

Start: 2008-08-31End: 2009-12-31Updated: 2022-04-25

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

CompletedNCT00839306

Eisai Inc.Gastroesophageal Reflux Disease (GERD)

Start: 2008-08-31End: 2010-01-31Updated: 2016-02-08